A simple method for screening for Farber disease on cultured skin fibroblasts

Clinica Chimica Acta

Volumn 245, Issue 1, 1996, Pages 61-71

  Chatelut, Martine ^a   Feunteun, Jean ^b   Harzer, Klaus ^c   Fensom, Anthony H ^d   Basile, Jean Pierre ^a   Salvayre, Robert ^a   Levade, Thierry ^a  

^a CHU RANGUEIL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

Ceramide; Diacylglycerol kinase; Farber disease; Lysosome; SV40 transformation

Indexed keywords

CERAMIDE; DIACYLGLYCEROL KINASE;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME ASSAY; FARBER DISEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SKIN FIBROBLAST; TECHNIQUE;

EID: 0030057008     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-8981(95)06173-8     Document Type: Article

References (39)

1. Moser HW, Moser AB, Chen WW, Schram AW. Ceramidase deficiency: Farber lipogranulomatosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic Basis of Inherited Disease, 6th ed. New York: McGraw-Hill: 1989;1645-1654.
2. Sugita M, Dulaney JT, Moser HW. Ceramidase deficiency in Farber's disease (lipogranulomatosis). Science 1972;178:1100-1102.
3. Dulaney JT, Milunsky A, Sidbury JB, Hobolth N, Moser HW. Diagnosis of lipogranulomatosis (Farber disease) by use of cultured fibroblasts. J Pediatr 1976;89:59-61.
4. Fensom AH, Benson PF, Neville BRG, Moser HW, Moser AE, Dulaney JT. Prenatal diagnosis of Farber 's disease. Lancet 1979;ii:990-992.
5. Gatt S. Enzymic hydrolysis and synthesis of ceramides. J Biol Chem 1963;238:3131-3133.
6. Gatt S. Enzymatic hydrolysis of sphingolipids. I. Hydrolysis and synthesis of ceramides by an enzyme from rat brain. J Biol Chem 1966;241:3724-3730.
7. Yavin E, Gatt S. Enzymatic hydrolysis of sphingolipids. VII. Further purification and properties of rat brain ceramidase. Biochemistry 1969;8:1692-1698.
8. Nilsson A. The presence of sphingomyelin and ceramide cleaving enzymes in the small intestinal tract. Biochim Biophys Acta 1969;176:339-347.
9. Sugita M, Williams M, Dulaney JT, Moser HW. Ceramidase and ceramide synthesis in human kidney and cerebellum: description of a new alkaline ceramidase. Biochim Biophys Acta 1975;398:125-131.
10. Stoffel W, Melzner I. Studies in vitro on the biosynthesis of ceramide and sphingomyelin. A reevaluation of proposed pathways. Hoppe Seyler's Z Physiol Chem 1980;361:755-771.
11. Momoi T, Ben-Yoseph Y, Nadler HL. Substrate specificities of acid and alkaline ceramidase in fibroblasts from patients with Farber disease and controls. Biochem J 1982;205:419-425.
12. Spence MW, Beed S, Cook HW. Acid and alkaline ceramidases of rat tissues. Biochem Cell Biol 1986;64:400-404.
13. Al BJM, Tiffany CW, Gomes de Mesquita DS, Moser HW, Tager JM, Schram AW. Properties of acid ceramidase from human spleen. Biochim Biophys Acta 1989;1004:245-251.
14. Chen WW, Moser AB, Moser HW. Role of lysosomal acid ceramidase in the metabolism of ceramide in human skin fibroblasts. Arch Biochem Biophys 1981;208:444-455.
15. Sutrina SL, Chen WW. Metabolism of ceramide containing endocytotic vesicles in human diploid fibroblasts. J Biol Chem 1982;257:3039-3044.
16. Kudoh T, Wenger DA. Diagnosis of metachromatic leukodystrophy, Krabbe disease and Farber disease after uptake of fatty acid-labeled cerebroside sulfate into cultured skin fibroblasts. J Clin Invest 1982;70:89-97.
17. Kudoh T, Velkoff MA, Wenger DA. Uptake and metabolism of radioactively labeled sphingomyelin in cultured skin fibroblasts from controls and patients with Niemann-Pick disease and other lysosomal storage disease. Biochim Biophys Acta 1983;754:82-92.
18. Inui K, Furukawa M, Nishimoto J, Okada S, Yabuuchi H. Metabolism of cerebroside sulphate and subcellular distribution of its metabolites in cultured skin fibroblasts derived from controls, metachromatic leukodystrophy, globoid cell leukodystrophy and Farber disease. J Inher Metab Dis 1987; 10:293-296.
19. Fusch C, Huenges R, Moser HW, Sewell AC, Roggendorf W, Kustermann-Kuhn B, Poulos A, Carey WF, Harzer K. A case of combined Farber and Sandhoff disease. Eur J Pediatr 1989;148;558-562.
20. Levade T, Tempesta MC, Salvayre R. The in situ degradation of ceramide, a potential lipid mediator, is not completely impaired in Farber disease. FEBS Lett 1993;329:306-312.
21. Levade T, Tempesta M, Moser HW, Fensom AH, Harzer K, Moser AB, Salvayre R. Sulfatide and sphingomyelin loading of living cells as tools for the study of ceramide turnover by lysosomal ceramidase. Implications for the diagnosis of Farber disease. Biochem Mol Med 1995;54:117-125.
22. Philippart M, Nakatani S, Zeilstra K, Tondeur M, Vamos-Hurwitz E, Pelc S. Farber's disease: ceramide accumulation in cultured fibroblasts [abstract]. Trans Am Soc Neurochem 1975;6:152.
23. Preiss JE, Loomis CR, Bell RM, Niedel JE. Quantitative measurement of sn-1-2-diacyglycerols. Meth Enzymol 1987;141:294-300.
24. Van Veldhoven P, Matthews TJ, Bolognesi DP, Bell RM. Changes in bioactive lipids, alkylacylglycerol and ceramide, occur in HIV infected cells. Biochem Biophys Res Commun 1992;187:209-216.
25. Jacquemin-Sablon H, Ganz L, Feunteun J. Transfer of immortality by transfection of genomic DNA from SV40 established cell lines into rat embryo fibroblasts. Biol Cell 1990;68:227-230.
26. Graber D, Salvayre R, Levade T. Accurate differentiation of neuronopathic and non-neuronopathic forms of Niemann-Pick disease by evaluation of the effective residual lysosomal sphingomyelinase activity in intact cells. J Neurochem 1994;63:1060-1068.
27. Smith P, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicin-choninic acid. Anal Biochem 1985;150:76-85.
28. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;275:497-509.
29. Krivit W, Hammarström S. Identification and quantification of free ceramides in human ptelets. J Lipid Res 1972;13:525-530.
30. Betts JC, Agranoff AB, Nabel GJ, Shayman JA. Dissociation of endogenous cellular ceramide from NF-xB activation. J Biol Chem 1994;269:8455-8458.
31. Haimovitz-Friedman A, Klan CC, Ehlerter D, Persaud RS, Mc Loughlin M, Fuks Z, Kolesnick RN. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 1994;80:525-535.
32. Sugita M, Iwamori M, Evans J, Cluer RHM, Dulaney JT, Moser HW. High performance liquid chromatography of ceramides: application to analysis in human tissues and demonstration of ceramide excess in Farber's disease. J Lipid Res 1974;15:223-226.
33. Iwamori M, Costello C, Moser HW. Analysis and quantification of free ceramide containing non-hydroxy and 2-hydroxy fatty acids, and phytosphingosine by high-performance liquid chromatography. J Lipid Res 1979;20:86-96.
34. Dulaney JT, Moser HW. Farber's disease (lipogranulomatosis). In: Glew RH, Peters SP, editors. Practical Enzymology of the Sphingolipidoses. New York: AR Liss 1977;283-296.
35. Harzer K, Paton BC, Poulos A, Kustermann-Kuhn B, Roggendorf W, Grisar T, Popp M. Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses. Eur J Pediatr 1989;149:31-39.
36. Levade T, Enders H, Schliephacke M, Harzer K. A family with a combined Farber and Sandhoff, isolated Sandhoff and isolated fetal Farber disease: postnatal exclusion and prenatal diagnosis of Farber disease using lipid loading tests on intact cultured cells. Eur J Pediatr 1995;154:643-648.
37. Tempesta MC, Salvayre R, Levade T. Functional compartments of sulphatide metabolism in cultured living cells: evidence for the involvement of a novel sulphatide-degrading pathway. Biochem J 1994;297:479-489.
38. Rutsaert J, Tondeur M, Vamos-Hurwitz E, Dustin P. The cellular lesions of Farber disease and their experimental reproduction in tissue culture. Lab Invest 1977;36:474-480.
39. Furuya T, Momoi T, Suzuki Y. Establishment of human fibroblast cell lines with lysosomal enzyme deficiency by transformation with origin-minus SV40 DNA. J Inher Metab Dis 1985;8:143-144.